Current Highlight from January 24, 2014
Genotoxicity of Doxorubicin in Rat
NCTR scientists showed that treatment of rats with doxorubicin induced a dose-dependent (1-3 mg/kg bw) increase in oxidative DNA damage in cardiac tissue and changes in the expression of DNA damage and repair genes. Doxorubicin is an anti-cancer drug most effective against pediatric lymphomas. However, it carries a risk of cardiotoxicity as a serious adverse effect which limits the life-time dose and its utility as a chemotherapeutic agent. This study suggests that the production of reactive oxygen species and the resulting persistent oxidative DNA damage may contribute to this cardiotoxicity. The research article describing this study was selected as the Editor’s Choice and is highlighted in the January 2014 issue of Environmental and Molecular Mutagenesis.
For additional information, please contact Mugimane Manjanatha, Ph.D., or Wei Ding, Ph.D., Division of Genetic and Molecular Toxicology, FDA/NCTR.
Final Reports On AIDS Therapeutics Toxicology Studies
The final reports for studies on the potential toxicity of 3’-azido-3’-deoxythymidine (AZT) and combinations of AZT, lamivudine, and nevirapine in genetically modified mice were published on the National Toxicology Program website. The studies showed that high doses of AZT given continuously or only during the perinatal and postnatal periods exhibited carcinogenic activity in a mouse model designed to detect genotoxic carcinogens. These studies were conducted at the FDA National Center for Toxicological Research under the auspices and funding of an Interagency Agreement between FDA/NCTR and NIEHS/NIH.
For additional information, please consult the final reports (GMM-14 and GMM-16) at the NTP website or contact Julian Leakey, Ph.D., Office of Scientific Coordination, FDA/NCTR.
-
No hay comentarios:
Publicar un comentario